Corbus Pharmaceuticals Holdings, Inc. (CRBP) earnings
CRBP earnings moved a median of +0.77% by the close. Quarterly and annual CRBP reports and results, each read against the price at its own news timestamp. Back to the CRBP overview →
19 measured CRBP earnings events.
Where these CRBP earnings landedvs 18 measured CRBP earnings reactions
| Middle 50% of CRBP earnings reactions | -6.60% to +4.16% |
|---|---|
| Median reaction (to close) | +0.77% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 CRBP earnings events with a measured close landed between -6.60% and +4.16%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Corbus Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +3.23% | +4.42% | |
| Form 10-Q Corbus Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.55% | +6.11% | |
| Form 10-K Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.52% | +3.40% | |
| Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Press release | +0.77% | +8.12% | |
| Form 10-Q Corbus Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -1.15% | — | |
| Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Press release | +1.84% | -6.32% | |
| Form 10-Q Corbus Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -0.50% | +0.66% | |
| Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Press release | -7.19% | -14.38% | |
| Form 10-Q Corbus Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -5.78% | -6.70% | |
| Form 10-K Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.73% | +0.88% | |
| Form 10-Q Corbus Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +0.46% | +1.73% | |
| Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | Press release | +0.45% | -4.39% | |
| Form 10-Q Corbus Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -3.23% | -11.39% | |
| Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.17% | +4.74% | |
| Form 10-Q Corbus Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +6.00% | |
| Form 10-K/A Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +1.16% | -1.42% | |
| Form 10-K Corbus Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +1.60% | +1.55% | |
| Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +3.21% | -10.26% | |
| Form 10-Q Corbus Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -13.18% |
Keep exploring
More CRBP: analyst actions → · SEC filings → · CRBP overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 306 | +0.04% | 51% |
| U.S. Physical Therapy, Inc. (USPH) | 304 | -0.03% | 46% |
| The Cooper Companies, Inc. (COO) | 303 | -0.21% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.